![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by cisco on March 25, 2002, at 21:23:04
In your travels through the web, researching psychopharmacology, has Anyone come across an explanation of the effects a Kappa Antagonist has at the Kappa1 and Kappa2 receptor sites of the human brain? Is Kappa Antagonism behavior the opposite of what a Kappa Agonist would precipitate?
Thanks for any help here.
Cisco
Posted by cisco on March 26, 2002, at 16:19:29
In reply to Kappa Antagonism, posted by cisco on March 25, 2002, at 21:23:04
Kappa Antagonism - From Opioids.com:
"Several lines of evidence, including the well-established observation that kappa opiate agonists produce dysphoria and psychotomimetic effects in humans, suggest that dysfunction of the endogenous kappa opioid system may contribute to opioid and cocaine addiction. The objective of this open-label study was to determine the effectiveness of a functional kappa antagonist as a treatment for opioid dependence. This was accomplished by combining a partial mu agonist/kappa antagonist (buprenorphine, 4 mg, sublingual) with a mu antagonist (naltrexone, 50 mg by mouth), theoretically leaving kappa antagonism as the major medication effect. Subjects were treatment-seeking heroin-dependent (as per Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) men (41 +/- 7 years old; 19 +/- 8 years heroin use) eligible for methadone maintenance. After inpatient detoxification and a naloxone-challenge test to verify that they were not physically dependent on opioids, subjects received naltrexone. Starting on the fourth day, patients also received liquid buprenorphine. All patients received medication at the clinic 6 days per week and a full program of psychosocial treatment. The major endpoints of the study were: pupil diameter to determine if the &mgr; agonist effects of buprenorphine were blocked by naltrexone, urine toxicology, and retention in treatment. Five patients (33%) completed the 3-month study. Four were abstinent from opioids and cocaine for the entire study, and one was abstinent from opioids and cocaine for the last 9 weeks. Six subjects dropped out due to either minor side effects or disliking the sensation of sublingual buprenorphine. There were no significant changes in pupillary diameter. The positive response to treatment exceeds that expected from naltrexone alone (90% dropout). These promising results suggest that controlled studies of this medication combination should be conducted."
OK. Not much of an answer. But it is better than nothing.
Cisco
Posted by Elizabeth on March 27, 2002, at 0:27:55
In reply to Kappa Antagonism, posted by cisco on March 25, 2002, at 21:23:04
> In your travels through the web, researching psychopharmacology, has Anyone come across an explanation of the effects a Kappa Antagonist has at the Kappa1 and Kappa2 receptor sites of the human brain?
It blocks them.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.